Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis

Next Previous
Trial Profile

A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 11 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ixekizumab (Primary)
  • Indications Non-radiographic axial spondyloarthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms COAST-X
  • Sponsors Eli Lilly and Company; Eli Lilly and Company (India) Pvt. Ltd

    • Most Recent Events

    • 03 Jun 2023 Post-hoc results (n=587) from COAST-V, COAST-X, COAST-W studies presented at the 24th Annual Congress of the European League Against Rheumatism.
    • 15 Feb 2023 Results(n=932: from the COAST program at 3 years, 1 year of the originating studies (COAST-V/-W/-X) and 2 years of COAST-Y) assessing safety and efficacy of ixekizumab in patients with axial spondyloarthritis published in The Journal of Rheumatology
    • 25 Oct 2022 Results assessing whether altASDAS index is truthful and discriminative in an external cohort in patients from COAST-V,COAST-W,COAST-X , published in the Rheumatology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top